Literature DB >> 15173904

Characterization of physicochemical properties of beryllium aerosols associated with prevalence of chronic beryllium disease.

Aleksandr B Stefaniak1, Mark D Hoover, Gregory A Day, Robert M Dickerson, Eric J Peterson, Michael S Kent, Christine R Schuler, Patrick N Breysse, Ronald C Scripsick.   

Abstract

Little is known about the physicochemical properties of beryllium aerosols associated with increased risk of beryllium sensitization and chronic beryllium disease (CBD). Such information is needed to evaluate whether airborne mass of beryllium is the appropriate metric of exposure or alternatively to provide a scientific basis for using information on particle size, surface area, and chemistry to support an improved exposure limit based on bioavailability through the inhalation and dermal routes of exposure. Thus, we used a suite of analytical techniques to characterize aerodynamically size-fractionated beryllium particles and powders that have been associated in epidemiological studies with higher prevalence of CBD. Aerosol particles were sampled from the ventilation systems of production lines for powders of beryllium metal and beryllium oxide and for ingots of copper-beryllium alloy. End product powders from the metal and oxide production lines were also collected. Particles released during production of beryllium metal were found to be complex, having heterogeneous composition, including reactive species such as fluorine. Powders from beryllium metal production were of high purity with only a minor component of beryllium oxide. Both particles and powders from oxide production were high-purity oxide. Particles released during production of copper-beryllium alloy were heterogeneous, being predominantly copper oxides. Thus, all particles and powders contain at least some beryllium in the form of beryllium oxide. These data justify efforts to thoroughly characterize beryllium aerosol properties when performing exposure assessments. The data also suggest that differences in particle chemical composition, size, number, and surface area may influence bioavailability of beryllium and contribute to risk of CBD. However, a scientific basis does not yet exist to replace mass as the current metric of exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173904     DOI: 10.1039/b316256g

Source DB:  PubMed          Journal:  J Environ Monit        ISSN: 1464-0325


  11 in total

1.  Biological exposure metrics of beryllium-exposed dental technicians.

Authors:  Moshe Stark; Yehuda Lerman; Arik Kapel; Asher Pardo; Yehuda Schwarz; Lee Newman; Lisa Maier; Elizabeth Fireman
Journal:  Arch Environ Occup Health       Date:  2014       Impact factor: 1.663

2.  The bioinorganic chemistry and associated immunology of chronic beryllium disease.

Authors:  Brian L Scott; T Mark McCleskey; Anu Chaudhary; Elizabeth Hong-Geller; S Gnanakaran
Journal:  Chem Commun (Camb)       Date:  2008-05-09       Impact factor: 6.222

3.  Characterisation of particulate matter on the receptor level in a city environment.

Authors:  Winson Chung; Qun Chen; Ogo Osammor; Andy Nolan; Xiaohui Zhang; Vida N Sharifi; Jim Swithenbank
Journal:  Environ Monit Assess       Date:  2011-04-21       Impact factor: 2.513

4.  Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry.

Authors:  Michael V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Donna L Cragle; William G Tankersley; Susan M Wells; Lee S Newman; Lisa A Maier
Journal:  Occup Environ Med       Date:  2011-04-02       Impact factor: 4.402

5.  Migration of Beryllium via Multiple Exposure Pathways among Work Processes in Four Different Facilities.

Authors:  Jenna L Armstrong; Gregory A Day; Ji Young Park; Aleksandr B Stefaniak; Marcia L Stanton; David C Deubner; Michael S Kent; Christine R Schuler; M Abbas Virji
Journal:  J Occup Environ Hyg       Date:  2014       Impact factor: 2.155

6.  Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.

Authors:  Mike V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Tasha E Fingerlin; Hiroe Sato; Lee S Newman; Lisa A Maier
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

Review 7.  Beryllium exposure: dermal and immunological considerations.

Authors:  Gregory A Day; Aleksandr B Stefaniak; Ainsley Weston; Sally S Tinkle
Journal:  Int Arch Occup Environ Health       Date:  2005-10-18       Impact factor: 3.015

Review 8.  Advances in identifying beryllium sensitization and disease.

Authors:  Dan Middleton; Peter Kowalski
Journal:  Int J Environ Res Public Health       Date:  2010-01-13       Impact factor: 3.390

9.  TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization.

Authors:  Morgan F Wade; Morgan K Collins; Denay Richards; Douglas G Mack; Allison K Martin; Charles A Dinarello; Andrew P Fontenot; Amy S McKee
Journal:  J Immunol       Date:  2018-09-05       Impact factor: 5.422

Review 10.  A reconsideration of acute Beryllium disease.

Authors:  Kristin J Cummings; Aleksandr B Stefaniak; M Abbas Virji; Kathleen Kreiss
Journal:  Environ Health Perspect       Date:  2009-04-28       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.